BPPS

BioMarin has created a safety net for all patients who are prescribed KUVAN so that, regardless of insurance status, all patients can gain access to KUVAN. The BioMarin Patient and Physician Support (BPPS) Program has a wide array of support options to help patients with coverage and access to KUVAN. BPPS is the gateway to other patient support services that can make access to KUVAN easier for your patients.

Patient support

For the patient with prescription drug coverage:

  • BPPS can help your patient obtain coverage for KUVAN and minimize out-of-pocket expense

For the patient who cannot afford the co-payment for KUVAN:

  • BPPS can refer your patient to the National Organization for Rare Disorders (NORD), a non-profit organization BioMarin is working in partnership with to provide financial assistance for patients

For the patient with no coverage for prescription drugs:

  • BPPS can help your patient research insurance options and refer your patient to the KUVAN Patient Assistance Program (K-PAP) if no coverage is found

For the patient who cannot afford medical food:

  • BPPS can refer your patient to NORD’s financial assistance program to help with qualified out-of-pocket expenses related to medical food

Once KUVAN has been approved by your patient’s insurance plan:

  • BPPS will refer the case to a specialty pharmacy that will send shipments of KUVAN directly to your patient’s home on an ongoing basis.

Clinician support

  • BPPS will handle the following action items:
    • Submit any required paperwork to insurance company, including paperwork for prior authorization and appeals as needed
    • Investigate benefits for prescription drugs
    • Identify any additional insurance plan requirements for coverage
    • Research alternative forms of insurance coverage for your patient, if needed, to provide KUVAN coverage, including enrollment in K-PAP as a last resort
  • Two easy steps to enroll patients in BPPS:
    1. Clinics complete a Statement of Medical Necessity (SMN) and Prescription form, while patients sign a Patient Authorization form that enables BPPS to work with health plans on their behalf
    2. Clinics fax the completed forms to BPPS at 1-866-863-3361

For more information

For more information about reimbursement or insurance issues, call BPPS at 1- 877-MY-KUVAN (1-877-695-8826) or e-mail bpps@BMRN.com.

For an overview of the support programs available, click here.

For an overview on BPPS, click here. If you have more questions about BPPS, please click here to see our Frequently Asked Questions (FAQs) About BPPS section.

For an overview on specialty pharmacies, click here. If you have more questions about specialty pharmacies, please click here to see our FAQs About Specialty Pharmacies section.

For an overview on K-PAP, click here. If you have more questions about K-PAP, please click here to see our FAQs About K-PAP section.

For an overview on NORD, click here. If you have more questions about NORD, please click here to see our FAQs About NORD section.

To enroll

Download HIPAA Patient Authorization release form in English.

Download Statement of Medical Necessity form.

Top

Indication

KUVAN® (sapropterin dihydrochloride) Tablets is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet.

Important Safety Information

Prolonged exposure to elevated blood Phe levels in PKU patients can result in severe neurologic damage. The initiation of KUVAN therapy does not eliminate the need for careful monitoring of blood Phe levels and ongoing dietary management.

Some patients receiving KUVAN can experience significant drops in blood Phe levels. Patients should be monitored closely to ensure that blood Phe levels do not fall too low.

Not all patients with PKU respond to treatment with KUVAN. Response to treatment can only be determined by a therapeutic trial of KUVAN.

KUVAN has not been studied in patients with liver or renal impairment. Patients who have these conditions should be carefully monitored when receiving KUVAN. Caution should be used with the administration of KUVAN to patients who are receiving levodopa and drugs that affect nitric oxide–mediated vasorelaxation or folate metabolism.

The most serious adverse reactions reported during KUVAN administration (regardless of relationship to treatment) were gastritis, spinal cord injury, streptococcal infection, testicular carcinoma, and urinary tract infection. Mild to moderate neutropenia was also noted. The most common adverse reactions were headache, diarrhea, abdominal pain, upper respiratory tract infection, pharyngolaryngeal pain, vomiting, and nausea.

Please read the full Prescribing Information by clicking here.

Kuvan patient Gina, age 42

BIOMARIN